Sun, Aug 31, 2014, 1:56 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Durata Therapeutics, Inc. (DRTX) Message Board

millycurry 1 post  |  Last Activity: Jun 25, 2014 4:11 PM Member since: Oct 15, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Trial Results On Ohr's Website Show The Significance of The Vision Gains in Squalamine Phase 2 Trial.

    It's a must read if you are short or long. This is NOT "data mining" as AF said in his article. It's real statistical evidence. AF has a vested negative bias and is not being objective. But investors need to be objective and the large Ophthalmologic companies will be objective and will be looking at the real data. Note how the vision gains compare to other treatments. Plus, these outstanding vision gains were with just the 2X per day dosing schedule. Visual acuity gains are what patients and docs want for their wet AMD/CNV disease patients. FDA has an approval path for vision gains. Remember, Ohr's phase II is not a regulatory approval trial. With Squalamine's great safety profile, It's a relatively easy step for Ohr to increase the dosing schedule and solution strength in a phase III trial to achieve even better vision gains and reduced need for injections. If vision gains are the criteria for not doing another injection, number of injections will be reduced. The criteria for the injections in Ohr's current phase II trial is based on fluid level rather than vision gains. Look at the Lucentis and Eyelea studies, none of them completely dry up the fluid. With a higher dosing, Squalamine drops will regress all CNV disease and increase vision gains much better as in the Elman trial case of disease regression of PDR with 4X per day dosing. Bottom line that objective industry people will understand, these kind of vision gains could not have occurred if the Squalamine drops were not working to regress the disease. Big Ophthalmologic pharma companies would love to have an eye drop that regresses CNV disease and increases vision gains. The market will figure this out. Due your own due diligence.

15.76+0.24(+1.55%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Burger King Worldwide, Inc.
NYSEFri, Aug 29, 2014 4:02 PM EDT
Synaptics Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT